NCT07415980

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

A Multicenter, Phase Ib/II Clinical Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide for Untreated Elderly Diffuse Large B-cell Lymphoma Patients With Double Expression of MYC and BCL2

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 68 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

Conditions

• Double Expressor DLBCL

Interventions

Type	Name	Description
DRUG	Polatuzumab Vedotin	1.8 mg/kg intravenously on Day 1 of each 21-day cycle.
DRUG	Rituximab (R)	375 mg/m² intravenously once weekly during Cycle 1, followed by administration on Day 1 of each subsequent cycle.
DRUG	Chidamide	20 mg, po, biw

Timeline

• Start date: 2026-04-01
• Primary completion: 2028-04-01
• Completion: 2031-04-01
• First posted: 2026-02-17
• Last updated: 2026-02-17